
Cancer Research p. 3001 - 3012 (2017)
Update date:2022-07-29
Topics:
Li, Rui
Ding, Chunyong
Zhang, Jun
Xie, Maohua
Park, Dongkyoo
Ding, Ye
Chen, Guo
Zhang, Guojing
Gilbert-Ross, Melissa
Zhou, Wei
Marcus, Adam I.
Sun, Shi-Yong
Chen, Zhuo G.
Sica, Gabriel L.
Ramalingam, Suresh S.
Magis, Andrew T.
Fu, Haian
Khuri, Fadlo R.
Curran, Walter J.
Owonikoko, Taofeek K.
Shin, Dong M.
Zhou, Jia
Deng, Xingming
A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here, we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compound. CYD-2-11 targeted the structural pocket proximal to S184 in the C-terminal region of Bax, directly activating its proapoptotic activity by inducing a conformational change enabling formation of Bax homooligomers in mitochondrial membranes. In murine models of small-cell and non-small cell lung cancers, including patient-derived xenograft and the genetically engineered mutant KRAS-driven lung cancer models, CYD-2-11 suppressed malignant growth without evident significant toxicity to normal tissues. In lung cancer patients treated with mTOR inhibitor RAD001, we observed enhanced S184 Bax phosphorylation in lung cancer cells and tissues that inactivates the propaoptotic function of Bax, contributing to rapalog resistance. Combined treatment of CYD-2-11 and RAD001 in murine lung cancer models displayed strong synergistic activity and overcame rapalog resistance in vitro and in vivo. Taken together, our findings provide preclinical evidence for a pharmacologic combination of Bax activation and mTOR inhibition as a rational strategy to improve lung cancer treatment.
Zouping Fuhai Technology Development Co., Ltd.
Contact:+0532-86934525 18660293207
Address:jiuhu town industrial park Zouping County,bingzhou Provincejiuhu town industrial park
Shanghai Hongbang Medical Technology CO.,. Ltd
Contact:13671516988 /18917636693
Address:Room1, No67 Building, Yongde Road369, Wujing Town, Minhang Districy, Shanghai CIty, China.
Melone Pharmaceutical Co., ltd
Contact:+86-411 82593920, 82593631
Address:No 232, JInma Roda, Development Zone, Dalian, China
Zhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
Zhejiang Hoshine Silicon Industry Co., Ltd.
Contact:86-573-89179966
Address:Zhapu Town, Pinghu City, Zhejiang, China
Doi:10.1021/ol400280b
(2013)Doi:10.1002/chir.22101
(2012)Doi:10.1021/acs.orglett.0c03521
(2020)Doi:10.1021/jo00043a025
(1992)Doi:10.1016/j.tetlet.2013.01.041
(2013)Doi:10.1021/ol702892e
(2008)